(Q38098888)

28 August 2017

Targeting MAPK pathway in melanoma therapy (English)

1 reference

28 August 2017

Yabin Cheng

1

1 reference

28 August 2017

Guohong Zhang

series ordinal

2

1 reference

28 August 2017

Gang Li

series ordinal

3

1 reference

28 August 2017

1 December 2013

1 reference

Cancer and Metastasis Reviews

28 August 2017

1 reference

28 August 2017

32

1 reference

28 August 2017

3-4

1 reference

28 August 2017

567-584

1 reference

https://scigraph.springernature.com/pub.10.1007/s10555-013-9433-9

28 August 2017

0 references

cites work

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Treatments for metastatic melanoma: synthesis of evidence from randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Melanoma and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Therapy for metastatic melanoma: the past, present, and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Transient and sustained ERK phosphorylation and nuclear translocation in growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

PKB binding proteins. Getting in on the Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Metastasis suppressor pathways--an evolving paradigm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Ras oncogenes and their downstream targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

The Ras superfamily at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Understanding signaling cascades in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Melanoma: from mutations to medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

BRAF signaling and targeted therapies in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Development of farnesyl transferase inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Stringent structural requirements for anti-Ras activity of S-prenyl analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Targeting NRAS in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Novel Ras antagonist blocks human melanoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Concepts in Ras-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Guilty as charged: B-RAF is a human oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

A dimerization-dependent mechanism drives RAF catalytic activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

The RAF proteins take centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

BRAF(E600) in benign and malignant human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

High frequency of BRAF mutations in nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Mutations of the BRAF gene in benign and malignant melanocytic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

An oncogenic role for ETV1 in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Oncogenic Braf induces melanocyte senescence and melanoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Use of human tissue to assess the oncogenic activity of melanoma-associated mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

PTEN signaling pathways in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Deregulated Akt3 activity promotes development of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

V599EB-RAF is an oncogene in melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Vemurafenib: the first drug approved for BRAF-mutant cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

BRAF targeted therapy changes the treatment paradigm in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

RAF265 inhibits the growth of advanced human melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Targeting the RAF-MEK-ERK pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

BRAF inhibitors: research accelerates in wake of positive findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

PD 98059 prevents establishment of the spindle assembly checkpoint and inhibits the G2-M transition in meiotic but not mitotic cell cycles in Xenopus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Adjuvant therapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

Metastasizing Melanoma Formation Caused by Expression of Activated N-RasQ61Kon an INK4a-Deficient Background

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9433-9

10.1007/S10555-013-9433-9

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference